The use of tyrosine kinase inhibitors (TKI) as HCC targeted therapies is an actively STAT3 may be suitable as a prognostic marker of HCC development, and may be a druggable target for HCC targeted therapy using regorafenib.
Introduction
Regorafenib (Stivarga), a novel oral multiple kinase inhibitor, potentially inhibits tumor growth through anti-angiogenesis (1). Several angiokinases such as VEGFR1/2, PDGFR-, and FGFR1 are believed to be major targets of regorafenib for cancer treatment (1, 2). Regorafenib was approved for the treatment of patients with metastatic colorectal cancer and advanced gastrointestinal stromal tumors by the US Food and Drug Administration in 2012. As the chemical structure of regorafenib is very similar to that of sorafenib, the first and only small molecule targeted therapy approved for HCC treatment, several in vitro studies and clinical trials have been initiated to evaluate the efficiency of regorafenib for HCC. The safety of regorafenib at a dose of 160 mg once daily has been validated in HCC patients following first-line sorafenib (3) . Participants are currently being recruited for a randomized, double blind, phase III study of regorafenib in patients with HCC who have progressed on sorafenib treatment (NCT01774344).
Protein tyrosine phosphatases (PTPs) are also vital regulators involved in many cellular signaling processes, which make PTPs potential prognostic markers and druggable targets. Src homology region 2 (SH2) domain-containing phosphatase 1, SHP-1, acts as a negative regulator of STAT3. The 3D structure of SHP-1 shows that the ligand-free SHP-1 has an auto-inhibited conformation through blocking catalytic 5 treatment of HCC. These results suggest that regorafenib has significant anti-HCC activity.
Materials and Methods

Cell
Inhibition of p-STAT3 signaling by regorafenib mediates HCC apoptosis.
To investigate the potential mechanism of action by which regorafenib induces apoptosis of HCC cells, we first examined the STAT3-related signal pathway which has been reported to be ubiquitously activated in HCC progression. As shown in Fig. 2A , regorafenib inhibited p-STAT3 and its related proteins including Mcl-1, cyclin D1, and survivin in a dose-dependent manner. Regorafenib exhibited significant p-STAT3 inhibition after an extremely short treatment span (Fig. 2B) . Regorafenib inhibited p-STAT3 signaling in dose-and time-dependent manners. In addition, regorafenib exhibited strong STAT3 inhibition as determined by p-STAT3 ELISA (Fig. 2C, left) .
Regorafenib demonstrated more potent inhibition of STAT3 than sorafenib, an approved clinical angiokinase inhibitor which also shows p-STAT3 inhibitory activity (Fig. 2C, right) . To clarify whether STAT3 inhibition induced by regorafenib sensitizes HCC cells to apoptosis, we analyzed the effect of regorafenib in PLC5 cell overexpressing STAT3. As shown in Fig, 2D , overexpression of STAT3 almost To explore the underlying mechanism by which regorafenib inhibits p-STAT3 signaling in-HCC, next, we examined potential inhibitors of p-STAT3 such as SHP-1, a known SH2 domain-containing protein tyrosine phosphatase (PTP) involved in dephosphorylation of STAT3, to clarify its anti-HCC effect. As shown in the results presented in Fig. 3A (left), we found that regorafenib increased SHP-1 activity at the same doses that inhibited p-STAT3 in PLC5 cells. Moreover, regorafenib also activated SHP-1 in other tested HCC cell lines at 10 M (Fig. 3A, right) . Importantly, both specific SHP-1 inhibitor and siRNA against SHP-1 (PTPN6) reversed the regorafenib-induced STAT3 inhibition and apoptosis, suggesting that SHP-1 may be involved in the effect of regorafenib on HCC (Fig. 3B) . Further, we found that regorafenib increased SHP-1 activity in purified recombinant SHP-1 proteins and SHP-1-containing IP lysate in vitro (Fig. 3C) , indicating that regorafenib activates SHP-1 by direct interaction. As the activity of SHP-1 was strongly regulated by the autoinhibited 3D structure, we further investigated the effect of the autoinhibited N-SH2 domain responsible for autoinhibition with catalytic PTPase, on regorafenib potency. We constructed wild-type, deletion of N-SH2 (dN1), and D61 single mutant 
regorafenib-induced apoptosis in a dose-dependent manner (Fig. 4C) . These results suggest that relieved SHP-1 counteracts regorafenib-induced anti-HCC effect.
Regorafenib, therefore, potentially relieves autoinhibition of SHP-1 and further inhibits p-STAT3 signals directly.
Regorafenib exhibited significant tumor inhibition in an HCC subcutaneous tumor model. To examine whether regorafenib displays anti-HCC potency in vivo, we tested regorafenib orally in a HCC-bearing subcutaneous xenograft mouse model.
Regorafenib-treated mice displayed significant tumor inhibition compared with the mice treated with vehicle (Fig. 5A, left) . The significant difference between regorafenib-treated (20 mg/kg/day) and vehicle-treated mice was found after 14 days of treatment (** P<0.05). In the end of treatment, regorafenib induced 34.72% of tumor volume in this PLC5-bearing animal model. Also, the average tumor weight of mice treated with regorafenib was lower than that of the vehicle-delivered mice in the end of treatment (Fig. 5A, right) . Notably, mice treated with 20 mg/kg/day regorafenib did not lose body weight until the end of the treatment (Fig. 5B) . To verify the detailed molecular mechanism determining regorafenib-induced anti-HCC potency, we collected the tumor lystate and investigated the SHP-1/p-STAT3-related signaling pathway. As shown in Fig. 5C , regorafenib inhibited p-STAT3 expression and increased the SHP-1 activity in vivo. Moreover, regorafenib showed better anti-tumor effect at the dose of 40 mg/kg/day treatment. Both the average tumor size and tumor weight of animals were less than 50% of those of control mice at the end of treatment (Fig. 5D ). Taken together, we found that regorafenib, a multi-target anti-angiokinase inhibitor, exhibited potent anti-HCC effect in vitro and in vivo through direct targeting of SHP-1/STAT3 signaling. 
Discussion
Although one receptor tyrosine kinase (RTK) inhibitor has been approved and several are currently being tested in clinical trials for the treatment of HCC, the unsatisfactory response rate of kinase inhibitors still highlights the urgent need for a precise understanding of which molecule(s) determine HCC progression and may be druggable. In this study, we disclosed that SHP-1 is a potential tumor suppressor, and a direct target of regorafenib for anti-HCC. Previously, SHP-1 was found to be 
candidate for prediction of HCC progression (Fig. 6) . Notably, STAT3 was believed to be a critical factor involved in microenvironment and cancer development. In our present HCC subcutaneous animal model, it is difficult for us to assay the effect of regorafenib on the tumor microenvironment and angiogenesis. As anti-angiogenesis has been considered as the main mechanism of action of TKIs for the treatment of HCC, the further investigation of regorafenib on angiogenesis, tumor microenvironment, and cancer metabolism will be needed to analyze the overall anti-HCC effect of regorafenib.
Here, we reported that regorafenib inhibited p-STAT3-mediated signaling by targeting autoinhibited SHP-1 directly to induce potent anti-HCC activity in vitro and in vivo.
The correlation between P-STAT3 expression and HCC prognosis further provided a mechanism-based rationale to target STAT3 by regorafenib. In conclusion, we suggest that STAT3 may be a useful prognostic marker for HCC progression and determine the sensitivity of regorafenib as a druggable target for patients with HCC. Columns, mean; bars, SE (n ≥ 3), *P < 0.05, **P < 0.01. 
